We characterized the incidence of central nervous system ( CNS ) metastases after treatment with trastuzumab emtansine ( T-DM1 ) versus capecitabine-lapatinib ( XL ) , and treatment efficacy among patients with pre-existing CNS metastases in the phase III EMILIA study .